Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.80 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.80 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.80 |
| ▸ | RAF1 | P04049 | 5/20 | 0.74 |
| ▸ | BRAF | P15056 | 5/20 | 0.74 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.70 |
| ▸ | TUBB | P07437 | 3/20 | 0.70 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.70 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mebendazole SCHEMBL29390263 | 1.00 | ABL1 (1.00) | ABL1ALDH1A1LMNACYP1A2KDR | |
| Mebendazole SCHEMBL3429179 | 0.90 | ABL1 (0.82) | ABL1ALDH1A1LMNACYP1A2KDR | |
| Mebendazole SCHEMBL15860 | 0.90 | ABL1 (0.82) | ABL1ALDH1A1LMNACYP1A2KDR | |
| Mebendazole SCHEMBL29409261 | 0.90 | ABL1 (0.82) | ABL1ALDH1A1LMNACYP1A2KDR | |
| Flubendazole SCHEMBL31704404 | 0.89 | KDR (1.00) | ABL1ALDH1A1LMNACYP1A2KDR | |
| Mebendazole SCHEMBL21051200 | 0.89 | ABL1 (0.80) | ABL1ALDH1A1LMNACYP1A2KDR | |
| SCHEMBL14375449 | 0.89 | KDR (0.80) | ABL1ALDH1A1LMNACYP1A2KDR | |
| Mebendazole SCHEMBL21051203 | 0.89 | ABL1 (0.80) | ABL1ALDH1A1LMNACYP1A2KDR | |
| Mebendazole SCHEMBL17262440 | 0.89 | ABL1 (0.80) | ABL1ALDH1A1LMNACYP1A2KDR | |
| Flubendazole SCHEMBL6232065 | 0.89 | KDR (1.00) | ABL1ALDH1A1LMNACYP1A2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025215232-A1 | A COMPOSITION COMPRISING A SAPONIN AND/OR AN ANTHELMINTIC AND/OR A MITOCHONDRIAL UNCOUPLER FOR THE TREATMENT OF LIVER DISEASE | RAINCASTLE BIO. LIMITED (GB) | 2025-10-16 | — | — | WO | claimed |
| EP-4101438-B1 | COMBINATION TREATMENT OF A SAPONIN AGENT AND AN ANTHELMINITIC AGENT AGAINST CANCER | RAINCASTLE BIO LTD (GB) | 2025-04-16 | — | — | EP | claimed |
| CN-117763602-A | Block chain based federation membership authentication method device and method for controlling the operation of a device System and method for controlling a system | 华中科技大学 | 2024-03-26 | — | — | CN | claimed |
| WO-2024028599-A1 | POLYMORPH OF THE KETOGLUTARATE OR P-TOLEUNESULPHONATE SALT OF MEBENDAZOLE | HEALX LTD (GB) | 2024-02-08 | — | — | WO | claimed |
| EP-4101438-A1 | COMBINATION TREATMENT OF A SAPONIN AGENT AND AN ANTHELMINITIC AGENT AGAINST CANCER | RainCastle bio. Limited (GB) | 2022-12-14 | — | — | EP | claimed |
| US-20190175560-A1 | MEBENDAZOLE CANCER THERAPIES AND METHODS OF USE | SHEPHERD THERAPEUTICS, INC. | 2019-06-13 | — | — | US | claimed |
| EP-2310009-B1 | PARENTERAL AND ORAL FORMULATIONS OF BENZIMIDAZOLES | UNIV HOUSTON (US) | 2017-12-20 | — | — | EP | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| WO-2025215232-A1 | A COMPOSITION COMPRISING A SAPONIN AND/OR AN ANTHELMINTIC AND/OR A MITOCHONDRIAL UNCOUPLER FOR THE TREATMENT OF LIVER DISEASE | RAINCASTLE BIO. LIMITED (GB) | 2025-10-16 | — | — | WO | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| EP-4101438-B1 | COMBINATION TREATMENT OF A SAPONIN AGENT AND AN ANTHELMINITIC AGENT AGAINST CANCER | RAINCASTLE BIO LTD (GB) | 2025-04-16 | — | — | EP | disclosed |
| US-20250049032-A1 | ETHYLENE SIGNALING ACTIVATOR MODULATES ROOT SYSTEM ARCHITECTURE | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2025-02-13 | — | — | US | disclosed |
| CN-119258057-A | Treatment of inflammatory diseases | 瑞柏斯制药有限公司 | 2025-01-07 | — | — | CN | disclosed |
| EP-0354761-B1 | Veterinary compositions for use against endoparasites, and their preparation | CHINOIN GYOGYSZER ES VEGYESZET (HU) | 1993-10-27 | — | — | EP | disclosed |
| US-5169846-A | Non-aqueous micellar solutions of anthelmintic benzimidazoles, closantel, or phenothiazine, and insect growth regulators | CROOKS MICHAEL J (AU) | 1992-12-08 | — | — | US | disclosed |
| EP-0427582-A2 | Non-aqueous micellar solutions of various drugs | Crooks, Michael John (AU) | 1991-05-15 | — | — | EP | disclosed |
| US-5006545-A | Veterinary compositions against endoparasites containing cypermethrin and albendazole | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1991-04-09 | — | — | US | disclosed |
| EP-0354761-A2 | Veterinary compositions for use against endoparasites, and their preparation | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1990-02-14 | — | — | EP | disclosed |
| EP-0090368-B1 | ANTHELMINTIC PREPARATIONS | HOECHST UK LIMITED (GB) | 1987-09-02 | — | — | EP | disclosed |
| EP-0224249-A1 | Amorphous benzimidazole derivatives | SYNTEX (U.S.A.) INC. (US) | 1987-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049032-A1 | ETHYLENE SIGNALING ACTIVATOR MODULATES ROOT SYSTEM ARCHITECTURE | GRK6, DGKK, RGS4 | ABL1 2814/4885ALDH1A1 4681/4885LMNA 4757/4885 |
| US-20190175560-A1 | MEBENDAZOLE CANCER THERAPIES AND METHODS OF USE | CYP3A43, HNMT, TUBB3 | ABL1 493/4885ALDH1A1 458/4885LMNA 3403/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | ABL1 1743/4885ALDH1A1 3081/4885LMNA 1817/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | ABL1 2396/4885ALDH1A1 568/4885LMNA 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.